Today Stories

Kalamazoo, Mich., USA – July 15, 2024 – Stryker (NYSE: SYK), a global leader in medical technologies, has completed the previously announced acquisition of Artelon, a privately held company specializing in innovative soft tissue fixation products for foot and ankle and sports medicine procedures. “Integrating Artelon’s portfolio into Stryker’s offerings will allow us to deliver best-in-class soft tissue fixation solutions,” said Tim Lanier, president of Stryker’s Trauma & Extremities division. “This acquisition strengthens our competitive edge. Leveraging Artelon’s unique synthetic technology and extensive expertise positions us to continue driving innovation and solidify our leadership in the foot and ankle and sports medicine segments.” Artelon’s technologies complement and expand th…

AstraZeneca today announced the successful completion of the acquisition of Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases. The acquisition bolsters the Alexion, AstraZeneca Rare Disease late-stage pipeline and expands on its bone metabolism franchise with the notable addition of eneboparatide (AZP-3601), a Phase III investigational therapeutic peptide with a novel mechanism of action designed to meet key therapeutic goals for hypoparathyroidism. In patients with hypoparathyroidism, a deficiency in parathyroid hormone (PTH) production results in significant dysregulation of calcium and phosphate, which can lead to life-altering symptoms and complications, including chronic kidney disease.1  This programme, together…

RESEARCH TRIANGLE PARK, N.C.– July 11, 2024 – IQVIA™ (NYSE:IQV) today announces that a leading, independent research firm, Everest Group, has recognized IQVIA as a Leader in its Life Sciences Regulatory and Medical Affairs Operations PEAK Matrix® Assessment 2024 survey, which measures both market impact and delivery effectiveness. The Everest Group report highlights IQVIA’s focus on innovation and its comprehensive portfolio of solutions that accelerates drug development from molecule to market. IQVIA partners with customers to plan, generate and disseminate trustworthy clinical and medical evidence which drives the right stakeholder dialogue throughout the asset lifecycle to advance regulatory and healthcare decision making that improves patient outcomes. A strong global footprint, along…

Cambridge, UK—10 July 2024: Cambridge Cognition, a leading provider of digital health solutions for brain health assessments has been included in the Bio-Hermes 2 project for its voice and touch-screen cognitive assessments, funded by the UK’s innovation agency, Innovate UK.  The Bio-Hermes 2 trial, led by the Global Alzheimer’s Platform Foundation (GAP), aims to determine how accurately digital and blood-based biomarkers, individually and in combination, can predict Alzheimer’s disease diagnosed definitively with positron emission tomography (PET) brain scans and clinical assessments. The upcoming trial will involve 1,000 participants over 24 months. Cambridge Cognition will collect speech biomarkers through its voice picture description tasks and conduct three touchscreen tasks tha…

Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases Hamburg, Germany, 10 July 2024:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced it has entered into a multi-year master research collaboration and option and license agreement with Pfizer. Under the agreement, Evotec and Pfizer will initially focus on early discovery research for metabolic and infectious diseases. The research will be carried out at Evotec’s sites in France, including Campus Curie in Toulouse, a state-of-the-art research site with capabilities spanning high throughput screening, in vitro and in vivo biology, proteomics and metabolomics. Evotec will receive research support funding from Pfizer and be eligibl…

Acquisition to expand Lilly's immunology pipeline with oral integrin therapies INDIANAPOLIS and WALTHAM, Mass., July 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Morphic Holding, Inc. (NASDAQ: MORF) today announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases. Morphic's lead program is a selective oral small molecule inhibitor of α4β7 integrin for the treatment of inflammatory bowel disease (IBD) that has the potential to improve outcomes and expand treatment options for patients. This molecule (known as MORF-057) is being evaluated in two Phase 2 studies in ulcerative colitis and one Phase 2 study in Crohn's disease. Additionally, Morphic is developing a precli…

Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness Designed to simplify administration, Vabysmo PFS provides retina specialists a ready-to-use option Vabysmo PFS will be available for people living with nAMD, DME and RVO Basel, 05 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the United States Food and Drug Administration (US FDA) has approved the Vabysmo® (faricimab) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of neovascular or ‘wet’ age-related macular degeneration (nAMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). Together, these three conditions affect close to 80 million people globally.1-4 The Vabysmo PFS…

LONDON, UK, (3rd July 2024) – Barrington James, a global leader in Life Science Recruitment, proudly announces the acquisition of S3 Science Recruitment, a firm renowned for its expertise in drug discovery, medical research, and the broader field of life sciences. Terms of the transaction were not disclosed. This strategic acquisition marks a significant milestone for Barrington James, enhancing the company's commitment to expanding its client-service capabilities and supporting the development of cutting-edge technology. This integration will provide clients with greater access to exceptional talent on both a permanent and temporary basis. Dan Barrington, CEO of Barrington James, stated: "We are thrilled to acquire S3 and expand our Human Capital services in Life Sciences. This acquisitio…

Boehringer Ingelheim and Gubra today announced the launch of the Phase 1 study (NCT06352437) of BI 3034701, a long-acting triple agonist peptide with a potential to become a next-generation and first-in-class obesity treatment.  More than 1 billion people worldwide live with obesity, and numbers are continuing to rise. Estimations show that by 2035, 24% of the entire world population will be affected by this disease.1 Obesity is a major risk factor for other cardiovascular, renal, and metabolic (CRM) diseases as well as for several types of cancer, which collectively are a leading cause of death worldwide. With the progression of BI 3034701, Boehringer Ingelheim further expands its pipeline of patient-centric solutions beyond weight loss for people living with obesity to achieve CRM he…

The PPD clinical research business will nearly double its laboratory footprint in northern Kentucky, add more than 250 jobs WILMINGTON, N.C.--(BUSINESS WIRE)-- The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, today announced the expansion of its central laboratory operations in Kentucky dedicated to accelerating pharmaceutical and biotech customers’ delivery of safe, effective medicines to patients. The business will expand its sample management and biorepository operations in a new 65,000-square-foot space in Covington, enabling further capability expansion at its existing site in nearby Highland Heights. Thermo Fisher’s $47.8 million investment is expected to create more than 250 new jobs across the two sites over the next eight ye…

The new research team at the BioMed X Institute in Heidelberg will develop a novel strategy to selectively target autoreactive plasma cells in autoimmune disease. HEIDELBERG/PARIS, June 3rd 2024 – BioMed X, an independent German biomedical research institute, and Servier, an international independent pharmaceutical company, announce the start of a new research team at the BioMed X Institute in Heidelberg to develop innovative strategies for neutralizing autoreactive plasma cells in the context of autoimmune diseases. Current therapeutic strategies for autoimmune diseases primarily focus on broadly suppressing the immune response, with significant side effects. More importantly, none of these treatments address one of the root causes of the disease, the autoreactive plasma cells that prod…

INDIANAPOLIS, June 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI's generative AI to invent novel antimicrobials to treat drug-resistant pathogens. Antimicrobial resistance (AMR) is one of the top public health and development threats across the global health landscape. "Our collaboration with OpenAI represents a groundbreaking step forward in the fight against the growing but overlooked threat of antimicrobial resistance," said Diogo Rau, executive vice president and chief information and digital officer at Lilly. "Generative AI opens a new opportunity to accelerate the discovery of novel antimicrobials and the development of custom, purpose-built technologies in the battle against drug-resistant pa…

In 2024, Novo Nordisk plans to boost its current investments, aiming to allocate USD 6.8 billion towards production, a significant increase from the previous year's investment of USD 3.9 billion*. Bagsværd, Denmark, 24 June 2024 – Novo Nordisk today announced plans to invest 4.1 billion US dollars (approx 27 billion Danish kroner) to build a second fill and finishing manufacturing facility in Clayton, North Carolina, and grow its ability to produce current and future injectable treatments for people with obesity and other serious chronic diseases. Marking one of the largest manufacturing investments in Novo Nordisk’s history, the expansion will add 1.4 million square feet of production space for aseptic manufacturing and finished production processes, doubling the combined square footage o…

The cobas® c 703 and cobas® ISE neo analytical units, deliver higher testing capacity and increased automation helping to improve laboratory workflows and advance patient care. The new cobas c 703 analytical unit offers industry-leading high throughput clinical chemistry testing1 with up to 2,000 tests per hour and 70 reagent positions, doubling the existing clinical chemistry throughput on cobas pro integrated solutions. The new cobas ISE neo analytical unit delivers more efficient ISE testing, reducing hands-on time through automated maintenance. Basel, 24 June 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of its new analytical units, cobas® c 703 and cobas® ISE neo, for the cobas® pro integrated solutions, in countries accepting the CE mark. The cobas pro integr…

Eight health centers across the U.S. participate in Innovation Incubator to find new ways to integrate healthy food into clinical care Now in its second year, the goal of the Innovation Incubator is to share what works with 1,400 health centers providing affordable care for 31+ million ABBOTT PARK, Ill. and BETHESDA, Md., June 20, 2024 /PRNewswire/ -- The global healthcare company Abbott (NYSE: ABT) and the National Association of Community Health Centers (NACHC) have joined together to increase access to healthy foods and improve health through the Innovation Incubator initiative. Eight community health centers have been selected to receive funding, expert guidance and training to design and test new solutions to help advance nutrition and improve care in their communities. One in…

The VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay is the first clinically approved in-situ hybridisation (ISH) test with the sensitivity to assess the full spectrum of B-cell lymphoma subtypes.1,2 The test helps differentiate a B-cell cancer from a normal, reactive immune response, providing diagnostic certainty for healthcare providers and their patients. B-cell lymphoma accounts for approximately 85 percent of non-Hodgkin lymphoma (NHL) cases, which is the tenth most common cancer worldwide.3 Basel, 20 June 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the first clinically approved, highly-sensitive in-situ hybridisation (ISH) test, the VENTANA® Kappa and Lambda Dual ISH mRNA Probe Cocktail assay, in countries accepting the CE Mark. The test is d…

The PPD clinical research business' new laboratory will enhance services in new and emerging therapeutic areas, add 350 new jobs to region WILMINGTON, N.C.--(BUSINESS WIRE)-- The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, today unveiled a new clinical research laboratory building at its good manufacturing practices (GMP) lab in Middleton, Wisconsin. The new 72,500-square-foot building increases the site’s chemistry, manufacturing and control (CMC) analytical capabilities as part of its clinical development and laboratory services focused on improving health by helping customers deliver life-changing medicines. “As research in biopharmaceutical therapies continues to rapidly expand, we are excited to expand our overall capacity and…

Suite of digital and data solutions designed to improve clinical trial efficiency, reduce data delays and simplify investigator site workflows BURLINGTON, N.C. , June 17, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp Global Trial Connect, a suite of central laboratory solutions aimed at increasing the speed of clinical trials where the heart of clinical research is conducted – investigator sites. "The patient-investigator-biopharma sponsor relationship is at the foundation of a successful clinical trial. Global Trial Connect simplifies the investigator workflow, improves the patient experience and ultimately enables biopharma sponsors to bring therapies to market faster," said Jon DiVincen…

400 million people are infected with Dengue every year. 100 million will show symptoms, and 40,000 will die from the disease. As the world’s fastest-growing mosquito-borne viral disease, a coordinated preventative effort is urgently needed to tackle Dengue. You can help by making World Dengue Day (WDD) a reality. Whilst WDD is widely backed and recognised on 15th June by the International Society for Neglected Tropical Diseases (ISNTD), Asian Dengue Voice and Action (ADVA) Group and dengue scientists around the world, it is not yet recognised by the United Nations. WDD would aim to raise public awareness of Dengue and encourage collaboration of scientific research and government disease control policies across the world. Vote in just one click to support the application to make WDD officia…

– Analysis Shows Manufacturing of Yescarta in Second-Line Treatment of Relapsed/Refractory Large B-cell Lymphoma Can Help Reduce Time from Leukapheresis to Infusion vs. Third-Line+ Treatment – – Data Builds on Previous Evidence on the Association Between Timely Infusion and Patient Outcomes – – Preliminary Results Supporting Safety and Feasibility of Outpatient Administration of Yescarta and Tecartus ® to be Presented – SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (Nasdaq: GILD), today announced results from three new analyses for Yescarta® (axicabtagene ciloleucel) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL), including both new clinical research and real-world evidence highlighting manufacturing and product characteristics of Yescarta, and outpatient admi…